Erenumab may represent an effective treatment strategy for individuals with highly therapy-refractory migraine, real-world evidence suggests
COVID-19 and rheumatic diseases: what factors may affect odds of hospitalization?
FDA joins multi-stakeholder effort to leverage real-world data in COVID-19 diagnostic testing space
Real-world industry round-up: integrated research platform launched to help aid understanding of COVID-19 impacts, outcomes and potential treatments
Look behind the lecture: the relevance of registry and real-world data throughout a product’s lifecycle
EMA calls for transparency and collaboration to ensure high-quality observational research in the context of COVID-19
ISPOR 2020: how may we enable faster access to multi-indication orphan products? Rare disease and orphan drug abstract highlights
Events, ISPOR, Health technology assessment, Medical devices, pharmaceuticals and vaccines, Methodology, Real-world evidence, Stakeholder engagement